Related Experiment Video
Updated: Aug 10, 2026

Neurogenesis Using P19 Embryonal Carcinoma Cells
Published on: April 27, 2019
p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced
M Omura-Minamisawa1, M B Diccianni, R C Chang
1Department of Pediatrics/Hematology-Oncology, University of California San Diego Medical Center, 200 West Arbor Drive, San Diego, CA 92103, USA.
Abstract:
p16 regulates the G(1)-S cell cycle transition by inhibiting the cyclin D-cyclin-dependent kinase (CDK)4/CDK6-mediated phosphorylation of retinoblastoma protein (pRb). We examined the possible derangement of the p16-CDK/cyclin D-pRb pathway in 40 primary neuroblastomas including 18 samples in the unfavorable stages (C and D) and 22 in the favorable stages (A, B, and Ds) by PCR, reverse transcription-PCR, Western blot, and immunohistochemistry and correlated the results with clinical outcome. No samples harbored alterations of the p16 gene. Interestingly, the samples in the unfavorable stages exhibited expression of p16 mRNA and protein more frequently than those in the favorable stages [mRNA, 9 of 18 (50%) versus 2 of 22 (9%), P = 0.006; protein, 5 of 16 (31%) versus 0 of 18 (0%), P = 0.013]. Alterations of the downstream components of the pathway were infrequent. pRb was deregulated in the majority of samples investigated [27 of 33 (82%), 24 with hyperphosphorylated pRb and 3 with no pRb protein]. The phosphorylation status of pRb did not correlate with p16 protein expression, suggesting that the elevated p16 protein may not be functioning properly to regulate the pathway. Among patients of all stages, p16 expression was significantly associated with a lower overall survival. There was no overexpression of MDM2, and loss of p14(ARF) expression and p53 mutation were infrequent events. Taken together, these findings suggest that up-regulated p16 expression may represent a unique feature of aggressive neuroblastoma.
Insights
Up-regulated p16 expression is more common in aggressive neuroblastoma and linked to poorer survival. This suggests elevated p16 may be a unique marker for advanced disease.
Area of Science:
- Molecular Biology
- Oncology
- Cell Cycle Regulation
Background:
- The p16 protein is crucial for regulating the G(1)-S cell cycle transition by inhibiting cyclin D-cyclin-dependent kinase (CDK)4/CDK6-mediated phosphorylation of retinoblastoma protein (pRb).
- Dysregulation of the p16-CDK/cyclin D-pRb pathway is implicated in various cancers, but its role in neuroblastoma, particularly concerning clinical outcome, requires further investigation.
Purpose of the Study:
- To investigate potential derangements in the p16-CDK/cyclin D-pRb pathway in primary neuroblastomas.
- To correlate findings with clinical stage and patient survival outcomes.
- To determine if p16 expression is associated with aggressive neuroblastoma characteristics.
Main Methods:
- Analysis of 40 primary neuroblastoma samples (18 unfavorable, 22 favorable stages).
- Utilized Polymerase Chain Reaction (PCR), reverse transcription-PCR, Western blot, and immunohistochemistry.
- Examined p16 gene alterations, mRNA and protein expression, and retinoblastoma protein (pRb) status.
Main Results:
- No p16 gene alterations were detected in any samples.
- Higher frequency of p16 mRNA and protein expression observed in unfavorable stage neuroblastomas compared to favorable stages (p=0.006 for mRNA, p=0.013 for protein).
- pRb was deregulated in 82% of samples; pRb phosphorylation status did not correlate with p16 protein expression.
- p16 expression significantly correlated with lower overall survival across all stages.
- Infrequent events included MDM2 overexpression, p14(ARF) loss, and p53 mutation.
Conclusions:
- Up-regulated p16 expression is a potential unique feature of aggressive neuroblastoma.
- Elevated p16 protein may not function properly in regulating the cell cycle pathway in these tumors.
- p16 expression serves as a significant prognostic marker associated with reduced survival in neuroblastoma patients.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
08:57Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
Related Concept Videos
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
Inhibition of Cdk Activity
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
DNA Damage Can Stall the Cell Cycle